Singapore, April 1, 2008: Singapore, a hub for the biomedical industry in the Asian region will be hosting BioMedical Asia 2008 from April 14-17 where in more than 1,000 leading global biomedical industry players are expected to take part in conference and exhibition. Biomedical Asia 2008 will be a unique platform to learn from successful case studies in Asia and forge strategic partnerships with industry movers and shakers, with six main conferences, seven focused industry summits and masterclasses, and the participation of 200 international speakers.
The four day event will bring together multi-national pharmaceutical companies, biotechs, research institutions, regulators, investors, physicians and other key stakeholders. Asia’s leading biopharmaceutical companies that will be represented in the conference include Chugai Pharma, Eisai Pharma, Kirin Pharma, LG Life Sciences, MerLion Pharma, Reliance Life Sciences, Shanghai Cell Engineering & Antibody Centre, Serum Institute of India. Participants will discuss latest discoveries, partnership opportunities, viable business ventures and best industry practices with leading industry representatives from the US and Europe as well as global biotech venture capitalists Novartis Venture Fund, Coastview Capital, MPM Capital and many others.
Singapore’s Minister for Trade & Industry, Mr Lim Hng Kiang, will officially open Biomedical Asia 2008. Mr Gordon Binder (Managing Director, Coastview Capital and Founder/Former CEO, Amgen), Mr Philippe Kourilsky (Chair of Molecular Immunology, College de France and Former Director General, Pasteur Institute, France), and Mr Ansbert Gadicke (Founder and General Partner, MPM Group) will speak at the opening plenary session.
Commenting on the significance of BioMedical Asia 2008, Mr Richard Ireland, Chief Executive – Asia Pacific, Terrapinn said, “Compared with North America and Europe, the biomedical sector in Asia Pacific is set to grow swiftly given its vast potential. As the industry is still young, it will be good for us to work more closely together and achieve strategic and synergistic alignment. Our ultimate goal for BioMedical Asia 2008 is to promote the learning and use of cost-effective drug development and manufacturing solutions to improve healthcare services and its accessibility. BioMedical Asia 2008 will also provide participants the opportunity to network with their peers from other related industries.”
Ms Aw Kah Peng, Assistant Managing Director, Singapore Economic Development Board added, “Situated at geographical crossroads between the East and the West, Singapore is a cosmopolitan city in the heart of Asia where global scientific and business leaders congregate. We are pleased to support Biomedical Asia 2008 and are confident that the conference and showcase will promote fruitful exchanges across both cultural and scientific boundaries.”
Speaking at the conference will be key people from across 140 pharmaceutical companies, biotech companies, life sciences investors, industry specialists, non-profit organizations, research institutions and universities, technology and solution providers, contract service providers, government and regulatory bodies, including those of Australia, China, Germany, France, Hong Kong, India, Japan, Malaysia, UK and the US. Delegates will have the opportunity to explore new products and new ways of thinking in the healthcare space.
|
SITE MAP 
Comment on this article
